Pilot trial with a tetravalent conjugate vaccine against small cell lung cancer
Pilot trial with a tetravalent conjugate vaccine against small cell lung cancer
批准号:
7325719
负责人:
PHILIP O. LIVINGSTON
金额:
$20.18万
依托单位国家:
美国
项目类别:
财政年份:
2007
资助国家:
美国
项目状态:
已结题
起止时间:
2007-09-25 至 2009-08-31
关键词:
Adjuvant ChemotherapyAgreementAlthaeaAntibodiesAntibody FormationAntigensBloodCancer PatientCancer VaccinesCenters for Disease Control and Prevention (U.S.)ClinicalClinical TrialsConjugate VaccinesContractsDiseaseDoseEnd PointEnzyme-Linked Immunosorbent AssayFoundationsGlobo-HGuanosine MonophosphateImmunizationIndividualInstitutionKeyhole Limpet HemocyaninLegal patentLicensingLocal TherapyLogisticsMalignant NeoplasmsMemorial Sloan-Kettering Cancer CenterMicrometastasisMulticenter TrialsNeoplasm MetastasisOperative Surgical ProceduresPatientsPharmacologic SubstancePhasePhase II Clinical TrialsPlacebo ControlPoliciesPolysialic AcidPreparationRadiation therapyRandomizedResidual stateSafetySmall Business Technology Transfer ResearchSurface AntigensTechnologyTechnology TransferTestingTimeVaccinationVaccine DesignVaccine ProductionVaccinesVial devicecancer cellimmunogenicimmunogenicitylung small cell carcinomaneoplastic cellpilot trialpreclinical studyvaccine evaluation
中文摘要
描述(由申请人提供):本1期STTR申请是针对SCLC的抗体诱导四价疫苗的初步临床试验。其基础是30年的研究,在此期间1)确定了针对癌细胞表面抗原的最佳抗体应答的疫苗设计,2)在临床前研究中证明了免疫接种在循环肿瘤细胞和微转移是主要靶点的最小疾病环境中的益处,3)定义了常见癌症表达的抗原,并鉴定了与SCLC疫苗相关的4种抗原,4)选择SCLC四价疫苗作为最有希望在随机2期试验中进行测试的疫苗,5)证实了针对这四种抗原的单价疫苗的安全性和免疫原性,并且确定了每种疫苗在化疗后辅助环境中的患者中的最佳剂量,以及6)疫苗生产技术成功转移到合同GMP设施(Althea Technologies,Inc.)从而可以制备用于多中心2期临床试验的缀合物。拟议的初步试验的主要终点是安全性和免疫原性。由于该四价疫苗中的单个结合物是由GMP设施根据合同制备的,而不是像过去那样在MSKCC制备的,并且将被装瓶并一起施用,而不是单独施用给单独的患者,因此安全性和免疫原性问题并不微不足道。如果该GMP级四价疫苗在本1期申请支持的中试试验中证明安全且具有免疫原性,则将提交2期STTR申请,以支持随机、安慰剂对照的2期试验。施用抗体和由本文提出的针对小细胞肺癌(SCLC)细胞表面抗原的四价疫苗诱导的抗体理想地适合于根除游离SCLC细胞和微转移。如果可以诱导足够滴度的抗体对抗这些抗原以从血液中消除肿瘤细胞并根除微转移,这将极大地改变我们治疗SCLC患者的方法。新转移的建立将不再可能,因此更积极的局部治疗包括已知最小残留转移的手术或放射治疗可能导致甚至转移性SCLC的长期控制。
英文摘要
DESCRIPTION (provided by applicant): This Phase 1 STTR application is for a pilot clinical trial of an antibody inducing tetravalent vaccine against SCLC. Its foundation is 30 years of studies during which time 1) vaccine design for optimal antibody responses against cancer cell surface antigens was determined, 2) the benefit of immunization in the minimal disease setting where circulating tumor cells and micrometastases are the primary targets was demonstrated in preclinical studies, 3) the antigens expressed by the common cancers were defined and the 4 antigens relevant for a SCLC vaccine identified, 4) the SCLC tetravalent vaccine was selected as the most promising for testing in a randomized Phase 2 trial, 5) the safety and immunogenicity of monovalent vaccines against these four antigens was confirmed and, the optimal dose of each vaccine in patients in the post chemotherapy adjuvant setting was determined, and 6) technology for vaccine production was successfully transferred to a contract GMP facility (Althea Technologies, Inc.) so that conjugates could be prepared for a multicenter Phase 2 clinical trial. The primary endpoints of the proposed pilot trial are safety and immunogenicity. Since the individual conjugates in this tetravalent vaccine were prepared under contract by GMP facilities instead of at MSKCC as in the past, and will be vialed and administered together rather than individually to separate patients, the issues of safety and immunogenicity are not trivial. If this GMP grade tetravalent vaccine proves safe and immunogenic in the pilot trial to be supported by this Phase 1 application, a Phase 2 STTR application to support the randomized, placebo-controlled Phase 2 trial will be submitted. Administered antibodies and antibodies induced by the tetravalent vaccine proposed here against small cell lung cancer (SCLC) cell surface antigens are ideally suited for eradication of free SCLC cells and micrometastasis. If antibodies of sufficient titer can be induced against these antigens to eliminate tumor cells from the blood and to eradicate micrometastasis, this would dramatically change our approach to treating the SCLC patient. Establishment of new metastasis would no longer be possible so more aggressive local therapies including surgery or radiation therapy of minimal known residual metastasis might result in long term control of even metastatic SCLC.
期刊论文(1)
专著(0)
科研奖励(0)
会议论文
DOI:
10.1007/s00262-011-1083-6
发表时间:
2012-01
期刊:
CANCER IMMUNOLOGY IMMUNOTHERAPY
影响因子:
5.8
作者:
[Krug, Lee M., Ragupathi, Govind, Hood, Chandra, George, Constantine, Hong, Feng, Shen, Ronglai, Abrey, Lauren, Jennings, Harold J., Kris, Mark G., Livingston, Philip O.]
通讯作者:
Livingston, Philip O.
Large Scale Synthesis of the Next Generation Synthetic Saponin Adjuvant TiterQuil
-
批准号:8779665
-
项目类别:
-
资助金额:$22.5万
-
财政年份:2014
-
负责人:PHILIP O. LIVINGSTON
-
依托单位:
Human Monoclonal Antibodies from Immunized Patient Lymphocytes
-
批准号:7405003
-
项目类别:
-
资助金额:$19.78万
-
财政年份:2008
-
负责人:PHILIP O. LIVINGSTON
-
依托单位:
Immune Monitoring
-
批准号:7728800
-
项目类别:
-
资助金额:$12.5万
-
财政年份:2008
-
负责人:PHILIP O. LIVINGSTON
-
依托单位:
Characterization of human antibodies to sialyl-Lewis A (sLeA) derived from patien
-
批准号:7801424
-
项目类别:
-
资助金额:$53.57万
-
财政年份:2008
-
负责人:PHILIP O. LIVINGSTON
-
依托单位:
Development of Antibody and T-Cell Inducing Vaccines
-
批准号:6952121
-
项目类别:
-
资助金额:$28.35万
-
财政年份:2005
-
负责人:PHILIP O. LIVINGSTON
-
依托单位:
Regulation by Immune Response to Vaccine by Botanicals
-
批准号:6946042
-
项目类别:
-
资助金额:$29.29万
-
财政年份:2005
-
负责人:PHILIP O. LIVINGSTON
-
依托单位:
GLYCOLIPID AND PROTEIN VACCINES AGAINST CANCER
-
批准号:6563801
-
项目类别:
-
资助金额:$29.18万
-
财政年份:2002
-
负责人:PHILIP O. LIVINGSTON
-
依托单位:
GLYCOLIPID AND PROTEIN VACCINES AGAINST CANCER
-
批准号:6423086
-
项目类别:
-
资助金额:$29.18万
-
财政年份:2001
-
负责人:PHILIP O. LIVINGSTON
-
依托单位:
CLINICAL TRIALS WITH ACTIVE AND PASSIVE IMMUNOTHERAPY AGAINST OVARIAN CANCER
-
批准号:6334957
-
项目类别:
-
资助金额:$26.78万
-
财政年份:2000
-
负责人:PHILIP O. LIVINGSTON
-
依托单位:
GLYCOLIPID AND PROTEIN VACCINES AGAINST CANCER
-
批准号:6300242
-
项目类别:
-
资助金额:$29.18万
-
财政年份:2000
-
负责人:PHILIP O. LIVINGSTON
-
依托单位:
DEVELOPMENT OF CANCER VACCINES
-
批准号:6102118
-
项目类别:
-
资助金额:$28.01万
-
财政年份:1999
-
负责人:PHILIP O. LIVINGSTON
-
依托单位:
CLINICAL TRIALS WITH ACTIVE AND PASSIVE IMMUNOTHERAPY AGAINST OVARIAN CANCER
-
批准号:6203171
-
项目类别:
-
资助金额:$26.78万
-
财政年份:1999
-
负责人:PHILIP O. LIVINGSTON
-
依托单位:
DEVELOPMENT OF CANCER VACCINES
-
批准号:6269152
-
项目类别:
-
资助金额:$26.93万
-
财政年份:1998
-
负责人:PHILIP O. LIVINGSTON
-
依托单位:
CLINICAL TRIALS WITH ACTIVE AND PASSIVE IMMUNOTHERAPY AGAINST OVARIAN CANCER
-
批准号:6102612
-
项目类别:
-
资助金额:$26.78万
-
财政年份:1998
-
负责人:PHILIP O. LIVINGSTON
-
依托单位:
DEVELOPMENT OF CANCER VACCINES
-
批准号:6236654
-
项目类别:
-
资助金额:$25.13万
-
财政年份:1997
-
负责人:PHILIP O. LIVINGSTON
-
依托单位:
CONSTRUCTION OF VACCINES AGAINST BREAST CANCER
-
批准号:2102174
-
项目类别:
-
资助金额:$19.46万
-
财政年份:1994
-
负责人:PHILIP O. LIVINGSTON
-
依托单位:
CLINICAL TRIALS WITH A POLYVALENT BREAST CANCER VACCINE
-
批准号:2008350
-
项目类别:
-
资助金额:$28.97万
-
财政年份:1994
-
负责人:PHILIP O. LIVINGSTON
-
依托单位:
CONSTRUCTION OF VACCINES AGAINST BREAST CANCER
-
批准号:2102176
-
项目类别:
-
资助金额:$20.48万
-
财政年份:1994
-
负责人:PHILIP O. LIVINGSTON
-
依托单位:
CLINICAL TRIALS WITH A POLYVALENT BREAST CANCER VACCINE
-
批准号:2882392
-
项目类别:
-
资助金额:$30.59万
-
财政年份:1994
-
负责人:PHILIP O. LIVINGSTON
-
依托单位:
CONSTRUCTION OF VACCINES AGAINST BREAST CANCER
-
批准号:2102175
-
项目类别:
-
资助金额:$19.92万
-
财政年份:1994
-
负责人:PHILIP O. LIVINGSTON
-
依托单位:
海外基金